We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The human monoclonal antibody denosumab ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Please provide your email address to receive an email when new articles are posted on . Long-term bisphosphonate users who switched to the human monoclonal antibody denosumab experienced a gain in hip ...

Madrid, Spain, 13 June 2019: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) finds the risk of bone mineral density (BMD) loss after denosumab ...

The human monoclonal antibody denosumab decreases bone resorption independently of previous treatment with bisphosphonates in patients with bone metastases. Bone metastases increase osteoclast ...

Among 1,032 Japanese patients on dialysis who started treatment for osteoporosis, denosumab use had a 45% lower risk for a composite of all fractures compared with oral bisphosphonates over 3 years ...

US FDA grants interchangeability designation to Celltrion's denosumab biosimilars, Stoboclo and Osenvelt: Incheon, South Korea Friday, October 31, 2025, 10:00 Hrs [IST] Celltrion, ...